Anhui Fengyuan Pharmaceutical Co Ltd (SHE:000153) — Market Cap & Net Worth
Market Cap & Net Worth: Anhui Fengyuan Pharmaceutical Co Ltd (000153)
Anhui Fengyuan Pharmaceutical Co Ltd (SHE:000153) has a market capitalization of $405.95 Million (CN¥2.77 Billion) as of October 14, 2026. Listed on the SHE stock exchange, this China-based company holds position #13382 globally and #3991 in its home market, demonstrating a -1.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anhui Fengyuan Pharmaceutical Co Ltd's stock price CN¥5.97 by its total outstanding shares 464685522 (464.69 Million).
Anhui Fengyuan Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Anhui Fengyuan Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $461.03 Million to $405.95 Million (-1.15% CAGR). Check 000153 share price today for real-time trading data and today's change.
Anhui Fengyuan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 000153 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.11x
Anhui Fengyuan Pharmaceutical Co Ltd's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.29x
Anhui Fengyuan Pharmaceutical Co Ltd's market cap is 4.29 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $576.71 Million | $2.03 Billion | $45.84 Million | 0.28x | 12.58x |
| 2017 | $353.90 Million | $2.58 Billion | $65.35 Million | 0.14x | 5.42x |
| 2018 | $230.42 Million | $3.01 Billion | $60.93 Million | 0.08x | 3.78x |
| 2019 | $302.66 Million | $3.24 Billion | $80.92 Million | 0.09x | 3.74x |
| 2020 | $402.94 Million | $3.32 Billion | $103.72 Million | 0.12x | 3.88x |
| 2021 | $548.55 Million | $3.65 Billion | $122.98 Million | 0.15x | 4.46x |
| 2022 | $631.55 Million | $4.00 Billion | $154.43 Million | 0.16x | 4.09x |
| 2023 | $442.76 Million | $4.28 Billion | $159.29 Million | 0.10x | 2.78x |
| 2024 | $416.83 Million | $4.28 Billion | $160.83 Million | 0.10x | 2.59x |
| 2025 | $426.35 Million | $3.86 Billion | $99.42 Million | 0.11x | 4.29x |
Competitor Companies of 000153 by Market Capitalization
Companies near Anhui Fengyuan Pharmaceutical Co Ltd in the global market cap rankings as of October 14, 2026. See Anhui Fengyuan Pharmaceutical Co Ltd net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Anhui Fengyuan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #526 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #581 globally with a market cap of $46.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #634 globally with a market cap of $42.99 Billion USD ( CN¥293.75 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #526 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #581 | GALDERMA GROUP AG | NYSE:GALDY | $46.88 Billion | $40.21 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.60 |
| #634 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.99 Billion | CN¥46.05 |
Anhui Fengyuan Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Anhui Fengyuan Pharmaceutical Co Ltd's market cap moved from $461.03 Million to $ 405.95 Million, with a yearly change of -1.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥405.95 Million | -4.78% |
| 2025 | CN¥426.35 Million | +2.28% |
| 2024 | CN¥416.83 Million | -5.86% |
| 2023 | CN¥442.76 Million | -29.89% |
| 2022 | CN¥631.55 Million | +15.13% |
| 2021 | CN¥548.55 Million | +36.14% |
| 2020 | CN¥402.94 Million | +33.13% |
| 2019 | CN¥302.66 Million | +31.35% |
| 2018 | CN¥230.42 Million | -34.89% |
| 2017 | CN¥353.90 Million | -38.63% |
| 2016 | CN¥576.71 Million | +25.09% |
| 2015 | CN¥461.03 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 13th, 2026 the market cap of Anhui Fengyuan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $405.95 Million USD |
| MoneyControl | $405.95 Million USD |
| MarketWatch | $405.95 Million USD |
| marketcap.company | $405.95 Million USD |
| Reuters | $405.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.